Abstract 37P
Background
Early-stage non-small cell lung cancer (NSCLC) has a 5-year survival rate of 63%. Current standards of care include surgery in the form of lobectomy or resection and stereotactic ablative radiotherapy (SABR). However, the current limitation of SABR is the moderate rates of reoccurrence in patients receiving treatment. We hypothesize that Neutrophil Extracellular Traps (NETs) may play a role in radio-resistance by decreasing T cell infiltration and activation in the tumor microenvironment.
Methods
The SABR-Bridge cohort is comprised of patients eligible for surgery that instead received neoadjuvant SABR followed by surgery 3-6 months later due to the SARS-COV-2 Pandemic. This cohort provides the unique ability to analyze changes in the microenvironment in non-responders after radiation. In addition, we use an orthotopic model of NSCLC with LLC1 cells injected into the left lung of wildtype or PAD4KO mice. Mice were then irradiated on day 7 and the tumor microenvironment was characterized with spectral flow cytometry and immunofluorescence spectroscopy.
Results
Result show that irradiated PAD4KO mice had significant decrease in both tumor volume and burden in comparison to controls. Further PD1+ CD8+ T cell infiltration in irradiated PAD4KO mice was significantly increased in comparison to controls. Survival analysis demonstrated that irradiated PAD4KO mice the received subsequent immonotherapy treatment had significantly better OS in comparison to wildtype controls.
Conclusions
It can be concluded that NETs play a role in radio resistance through decreasing T cell infiltration in a NSCLC orthotopic setting. Further, in PAD4KO preclinical models, adjuvant immunotherapy was more effective conferring greater OS. Future implications include the use of DNase or PAD4i to potentially increase radiation induced T cell infiltration in the context of adjuvant immune checkpoint-blockade therapy (ICI) in patient settings.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
CIHR.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract